SCHEMBL6775461

SCHEMBL6775461

O=C(O)c1ccc(CO)cc1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.56
FOLH1 Q04609 2/20 0.56
PTPN2 P17706 1/20 0.56
PTPN6 P29350 1/20 0.56
HDAC7 Q8WUI4 4/20 0.54
ACMSD Q8TDX5 2/20 0.53
PLA2G2A P14555 2/20 0.48
HDAC1 Q13547 2/20 0.47
HDAC4 P56524 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
HNF4A P41235 2/20 0.46
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
AKR1C1 Q04828 1/20 0.45
DCLRE1A Q6PJP8 1/20 0.45
DCLRE1B Q9H816 1/20 0.45
PLA2G10 O15496 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6679972 0.86 PTPN1 (0.53) PTPN1FOLH1PTPN2PTPN6HDAC7
SCHEMBL27650066 0.86 CSNK2A1 (0.53) PTPN1FOLH1PTPN2PTPN6HDAC7
SCHEMBL10909137 0.86 PTPN1 (0.53) PTPN1FOLH1PTPN2PTPN6HDAC7
SCHEMBL6777102 0.86 PTPN1 (0.53) PTPN1FOLH1PTPN2PTPN6HDAC7
SCHEMBL9407400 0.85 FOLH1 (0.75) PTPN1FOLH1PTPN2PTPN6ACMSD
SCHEMBL24578096 0.84 HDAC7 (0.60) PTPN1FOLH1PTPN2PTPN6HDAC7
SCHEMBL29775262 0.84 HDAC7 (0.60) PTPN1FOLH1PTPN2PTPN6HDAC7
SCHEMBL29118550 0.83 HDAC7 (0.47) PTPN1FOLH1PTPN2PTPN6HDAC7
SCHEMBL9509918 0.83 METAP2 (0.53) PTPN1FOLH1PTPN2PTPN6HDAC7
SCHEMBL29100387 0.83 BACE1 (0.64) PTPN1FOLH1PTPN2PTPN6HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105745187-B For treating the compound of tumor disease 科隆大学 2019-04-30 CN disclosed
CN-105745187-A Compounds useful in the treatment of neoplastic diseases 科隆大学 2016-07-06 CN disclosed
US-6693123-B2 (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA UNIVERSITY OF PITTSBURGH 2004-02-17 US disclosed
EP-0873123-B1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 2003-04-09 EP disclosed
US-20020193596-A1 Inhibitors of protein isoprenyl transferases UNIVERSITY OF PITTSBURGH (US) 2002-12-19 US disclosed
US-6310095-B1 INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE UNIVERSITY OF PITTSBURGH 2001-10-30 US disclosed
US-6221865-B1 INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. UNIVERSITY OF PITTSBURGH 2001-04-24 US disclosed
US-6204293-B1 INHIBITING POST-TRANSLATIONAL MODIFICATION OF THE ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE, PROTEIN GERANYLGERANYLTRANSFERASE, OR BOTH UNIVERSITY OF PITTSBURGH 2001-03-20 US disclosed
EP-0873123-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-02-03 EP disclosed
WO-1998050031-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 WO disclosed
WO-1998050030-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 WO disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193596-A1 Inhibitors of protein isoprenyl transferases LANCL1, FNTB, DHCR7 PTPN1 2866/4885FOLH1 3423/4885PTPN2 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.